

Empagluco®

Empagliflozin Tablets
10 mg / 25 mg



Your Health, Our Ambition



It's Time To Get To The Heart Of What Matters

Significantly reduced risk of cv death for adults who have type 2 diabetes and known heart disease.



Empagluco[®]

Empagliflozin Tablets
10 mg / 25 mg

Empagluco Is The First Type 2 Diabetes Pill To Reduce The Risk Of Cardiovascular (CV) Death

While all type 2 diabetes treatments lower blood sugar, Empagluco is the first type 2 diabetes pill to go beyond lowering A1C with a lifesaving cardiovascular (CV) benefit.

Lower A1C

When added to metformin in a 24-week study, Empagluco helped some people reach an A1C of less than **7%**— approximately 6 times better, on average, than those taking metformin alone (0.1% decrease).

Reduced fasting blood sugar levels

People taking Empagluco alone also reduced their fasting blood sugar levels (that's the measurement taken before breakfast) by an average of 19 or 25 points (mg/dL).*

Weight Loss

In patients with type 2 diabetes empagliflozin increased urinary glucose excretion to approximately 78 g/day, and thus empagliflozin has been associated with **weight loss**.^{1*} People lost 2–3% of their body weight, on average.

Reduce BP

When Empagluco was used alone or with metformin, it helped some people lower systolic blood pressure (the top number of the blood pressure reading) a little bit, too.

Mode of action

- Empagliflozin improves **glycaemic control** in patients with type 2 diabetes by reducing **renal glucose reabsorption**¹
- The MOA is independent of beta cell function and insulin pathway, contributing to a **low risk of hypoglycaemia**.¹

Oral once daily dosing

The starting dose is 10 mg empagliflozin in once daily for mono therapy and add-on combination therapy with other drugs for treatment of diabete.


Empagliflozin Increases Cardiac Energy Production in Diabetes
Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

Subodh Verma, Sonia Rawat, Kim L. Ho, Cory S. Wagg, Liyan Zhang, Hwee Teoh, John E. Dyck, Golam M. Uddin, Gavin Y. Oudit, Eric Mayoux, Michael Lehrke, Nikolaus Marx and Gary D. Lopaschuk 2018

RX

Empagluco[®]

A better treatment approach



Varian Pharmed Pharmaceuticals
Unit 9, No 5, Golshan3 Bldg, Laleh Blvd,
Sattari ExpWay, Tehran 1473896381 - IRAN
Tel: +98 (21) 44483009
Fax: +98 (21) 44483649
www.varianpharmed.com

